



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Att for patents

Food and Drug Administration  
Rockville MD 20857



OCT 24 1996

RECEIVED  
OCT 3 1996  
OFFICE OF PATENT  
ADMINISTRATION

#11

Re: CAMPTOSAR®

Stephen G. Kunin  
Deputy Assistant Commissioner for  
Patent Policy and Projects  
Office of the Assistant Commissioner for Patents  
U.S. Patent and Trademark Office  
Crystal Park Building 2, Suite 919  
Washington, D.C. 20231

Dear Mr. Kunin:

This is in regard to the application for patent term extension for U.S. Patent No. 4,604,463 filed by Kabushiki Kaisha Yakult Honsha under 35 U.S.C. § 156. The human drug product claimed by the patent is CAMPTOSAR® (irinotecan hydrochloride), which was assigned New Drug Application (NDA) No. 20-571.


A review of the Food and Drug Administration's official records indicates that this product was subject to a regulatory review period before its commercial marketing or use, as required under 35 U.S.C. § 156(a)(4). Our records also indicate that it represents the first permitted commercial marketing or use of the product.

The NDA was approved on June 14, 1996, which makes the submission of the patent term extension application on August 13, 1996, timely within the meaning of 35 U.S.C. § 156(d)(1).

Should you conclude that the subject patent is eligible for patent term extension, please advise us accordingly. As required by 35 U.S.C. § 156(d)(2)(A) we will then determine the applicable regulatory review period, publish the determination in the Federal Register, and notify you of our determination.

Please let me know if we can be of further assistance.

Sincerely,

  
Ronald L. Wilson, Director  
Health Assessment Policy Staff  
Office of Health Affairs

cc: Leonard R. Svensson  
Birch, Stewart, Kolasch, Birch, LLP  
P.O. Box 747  
Falls Church, VA 22040-0747